The Radiation Therapy Oncology Group (RTOG) evaluated the prognostic significance of Nestin expression in newly diagnosed GBM patients treated in prior prospective clinical trials, given the variable expression of Nestin in GBM observed in another study and its possible role as a marker for a dedifferentiated and potentially it aimed to determine whether there is a more aggressive phenotype.47 The gene discussed is NES; the disease is glioblastoma.